Anti-Coagulants - BRICS

BRICS

In 2024, the projected revenue in the Anti-Coagulants market for the country in BRICS is estimated to reach US$4.81bn.
Looking ahead, it is expected that the revenue will experience a compound annual growth rate (CAGR 2024-2029) of 7.98%, leading to a market volume of US$7.06bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue in the Anti-Coagulants market, with US$16,740.00m in 2024.
In Brazil, the increasing prevalence of cardiovascular diseases has led to a growing demand for anti-coagulants in the market.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in BRICS has been steadily growing in recent years, with each country showing unique trends and developments.

Customer preferences: Patients in BRICS countries have shown a preference for oral anti-coagulants over traditional injectable options. This is due to the convenience and ease of administration of oral medications. Additionally, patients are increasingly seeking treatments with fewer side effects and lower risks of bleeding.

Trends in the market: In Brazil, the Anti-Coagulants market has been driven by an aging population and increasing prevalence of cardiovascular diseases. The market has seen a shift towards the use of direct oral anti-coagulants, as they offer improved safety and efficacy compared to traditional options.Russia has seen a rise in the use of anti-coagulants due to an increase in the number of patients with atrial fibrillation and venous thromboembolism. The market has been dominated by vitamin K antagonists, but there has been a recent shift towards direct oral anti-coagulants.India has a large patient population and a high burden of cardiovascular diseases. The Anti-Coagulants market has seen a trend towards the use of direct oral anti-coagulants, as they offer improved patient outcomes and lower risks of bleeding.In China, the Anti-Coagulants market has been driven by an aging population and increasing prevalence of cardiovascular diseases. The market has seen a shift towards the use of direct oral anti-coagulants, as they offer improved safety and efficacy compared to traditional options.

Local special circumstances: In Brazil, the government has implemented policies to increase access to healthcare, which has led to an increase in the number of patients seeking treatment for cardiovascular diseases. However, the high cost of direct oral anti-coagulants has limited their availability to only those who can afford them.In Russia, the healthcare system is government-funded, which has led to limited access to newer anti-coagulant treatments. Additionally, there is a lack of awareness among healthcare providers and patients about the benefits of direct oral anti-coagulants.India has a large population and a fragmented healthcare system, which has led to challenges in accessing anti-coagulant treatments. Additionally, there is a lack of awareness among patients about the importance of anti-coagulant therapy in preventing cardiovascular diseases.China has a large patient population and a growing middle class, which has led to an increase in demand for healthcare services. However, the healthcare system is still developing, and there are challenges in accessing newer anti-coagulant treatments.

Underlying macroeconomic factors: The BRICS countries have experienced economic growth in recent years, which has led to an increase in healthcare spending. Additionally, an aging population and increasing prevalence of cardiovascular diseases have driven demand for anti-coagulant treatments. However, the high cost of newer treatments and limited access to healthcare services have limited the growth of the Anti-Coagulants market in some countries.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.